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Purpose of the study
Pharmacokinetic and pharmacodynamic interactions
between antiretroviral and substance abuse therapies can
adversely influence efficacy and toxicity of either or both
agents. The primary objective of this study was to assess
the effect of steady-state tipranavir 500 mg co-adminis-
tered with ritonavir 200 mg (TPV/r) twice daily on the
steady-state pharmacokinetics of buprenorphine/
naloxone (BUP/NAL) in subjects chronically treated with
BUP/NAL.
Methods
This was a multiple dose, open-label, sequential, non-ran-
domized study in HIV-negative subjects stabilized on at
least 3 weeks of BUP/NAL therapy.
Summary of results
At day 7 of concomitant administration, buprenorphine
AUC and Cp24 h were not affected by co-administered
TPV/r (<6% change relative to BUP/NAL alone) while
Cmax decreased approximately 14%. Norbuprenorphine,
the major BUP metabolite, AUC, Cmax and Cp24 h were
decreased approximately 80% when co-administered with
TPV/r. NAL AUC and Cmax were decreased approximately
44% and 36%, respectively, when coadministered with
TPV/r. The last measurable plasma NAL concentration
(Clast) in the concentration-time profile was decreased by
20%. Despite these pharmacokinetic effects, there was no
clinical evidence of opioid withdrawal as measured by the
Objective Opiate Withdrawal Scale and the Subjective
Opiate Withdrawal Scale, and no need to modify
buprenorphine dose. Because the study design did not
include treatment with tipranavir and ritonavir alone,
comparison was made to data from historical controls.
TPV Cmax was unchanged (~6% decrease) while AUC and
Cp12 h decreased 26% and 39%, respectively. Ritonavir
concentrations at or near the end of the 12-h TPV/r dosing
interval (Clast) were similar to historical controls, but
ritonavir geometric mean Cmax and AUC were lower in
the present study by 40–50% and 35%, respectively.
Conclusion
The results of this study indicate that no dosage modifica-
tion of buprenorphine/naloxone is required when it is co-
administered with TPV/r. The mechanism by which BUP/
NAL affected the pharmacokinetic parameters of TPV is
unclear; however, it is likely that the effect of lower
plasma RTV exposure contributed substantially to the
effect on tipranavir. Caution should be used when com-
bining BUP/NAL with TPV/r as tipranavir may be less
effective due to decreased tipranavir plasma concentra-
tions in patients taking these agents concomitantly.
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